Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AssigneeMerck Frosst Canada, Inc.
InventorsYves Leblanc, David Powell, Yeeman K. Ramtohul, Serge Léger
Life of this patent
Estimating the term…
Abstract
Azacycloalkane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.
Claims19
A compound of structural formula I:
- or a pharmaceutically acceptable salt thereof;
- wherein
- each m is independently an integer from 0 to 4;
- each n is independently an integer from 0 to 2;
- each s is independently an integer from 1 to 3;
- each t is independently an integer from 1 to 3;
- q is 0 or 1;
- r is 0 or 1;
- Z is O, S, or NR4;
- X—Y is N—CRaRb, CR14—S(O)0-2, or CR13—CRaRb;
- W is heteroaryl selected from the group consisting of:
- Ar is phenyl, naphthyl, or heteroaryl optionally substituted with one to five R3 substituents;
- Ra and Rb are each independently hydrogen or C1-3 alkyl, wherein alkyl is optionally substituted with one to three substituents independently selected from fluorine and hydroxy;
- R1 is heteroaryl selected from the group consisting of:
- wherein Rc is —(CH2)mCO2H, —(CH2)mCO2C1-3 alkyl, —(CH2)m-Z-(CH2)pCO2H, or —(CH2)m-Z-(CH2)pCO2C1-3 alkyl, wherein each (CH2) methylene group is optionally substituted with one or two substituents selected from the group consisting of C1-4 alkyl, fluorine, oxo, and hydroxy;
- and wherein said R1 heteroaryl ring is optionally substituted with one substituent independently selected from the group consisting of cyano, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylsulfonyl, and trifluoromethyl;
- each R2 is independently selected from the group consisting of:
- hydrogen,
- halogen,
- hydroxy,
- cyano,
- amino,
- nitro,
- C1-4 alkyl, optionally substituted with one to five fluorines,
- C1-4 alkoxy, optionally substituted with one to five fluorines,
- C1-4 alkylthio, optionally substituted with one to five fluorines,
- C1-4 alkylsulfonyl,
- carboxy,
- C1-4 alkyloxycarbonyl, and
- C1-4 alkylcarbonyl;
- each R3 is independently selected from the group consisting of:
- C1-6 alkyl,
- C2-6 alkenyl,
- (CH2)n-phenyl,
- (CH2)n-naphthyl,
- (CH2)n-heteroaryl,
- (CH2)n-heterocyclyl,
- (CH2)nC3-7 cycloalkyl,
- halogen,
- nitro,
- (CH2)nOR4,
- (CH2)nN(R4)2,
- (CH2)nC≡N,
- (CH2)nCO2R4,
- (CH2)nNR4SO2R4
- (CH2)nSO2N(R4)2,
- (CH2)nS(O)O0-2R4,
- (CH2)nNR4C(O)N(R4)2,
- (CH2)nC(O)N(R4)2,
- (CH2)nNR4C(O)R4,
- (CH2)nNR4CO2R4,
- (CH2)nC(O)R4,
- O(CH2)nC(O)N(R4)2,
- (CH2)s-Z-(CH2)t-phenyl,
- (CH2)s-Z-(CH2)t-naphthyl,
- (CH2)s-Z-(CH2)t-heteroaryl,
- (CH2)s-Z-(CH2)t-heterocyclyl,
- (CH2)s-Z-(CH2)t—C3-7 cycloalkyl,
- (CH2)s-Z-(CH2)t—OR4,
- (CH2)s-Z-(CH2)t—N(R4)2,
- (CH2)s-Z-(CH2)t—NR4SO2R4,
- (CH2)s-Z-(CH2)t—C≡N,
- (CH2)s-Z-(CH2)t—CO2R4,
- (CH2)s-Z-(CH2)t—SO2N(R4)2,
- (CH2)s-Z-(CH2)t—S(O)0-2R4,
- (CH2)s-Z-(CH2)t—NR4C(O)N(R4)2,
- (CH2)s-Z-(CH2)t—C(O)N(R4)2,
- (CH2)s-Z-(CH2)t—NR4C(O)R4,
- (CH2)s-Z-(CH2)t—NR4CO2R4,
- (CH2)s-Z-(CH2)t—C(O)R4,
- CF3,
- CH2CF3,
- OCF3, and
- OCH2CF3;
- in which phenyl, naphthyl, heteroaryl, cycloalkyl, and heterocyclyl are optionally substituted with one to three substituents independently selected from halogen, hydroxy, C1-4 alkyl, trifluoromethyl, and C1-4 alkoxy;
- and wherein any methylene (CH2) carbon atom in R3 is optionally substituted with one to two groups independently selected from fluorine, hydroxy, and C1-4 alkyl;
- or two substituents when on the same methylene (CH2) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group;
- each R4 is independently selected from the group consisting of
- hydrogen,
- C1-6 alkyl,
- (CH2)n-phenyl,
- (CH2)n-heteroaryl,
- (CH2)n-naphthyl, and
- (CH2)nC3-7 cycloalkyl;
- wherein alkyl, phenyl, heteroaryl, and cycloalkyl are optionally substituted with one to three groups independently selected from halogen, trifluoromethyl, C1-4 alkyl, and C1-4 alkoxy;
- or two R4 groups together with the atom to which they are attached form a 4- to 8-membered mono- or bicyclic ring system optionally containing an additional heteroatom selected from O, S, NH, and NC1-4 alkyl;
- R5, R6, R7, R8, R9, R10, R11, and R12 are each independently hydrogen, fluorine, or C1-3 alkyl, wherein alkyl is optionally substituted with one to three substituents independently selected from fluorine and hydroxy;
- R13 is hydrogen, C1-3 alkyl, fluorine, or hydroxy;
- and
- each R14 is hydrogen or C1-3 alkyl.
A compound which is
- or a pharmaceutically acceptable salt thereof.
A compound which is
- or a pharmaceutically acceptable salt thereof.
A compound which is
- or a pharmaceutically acceptable salt thereof.
A compound which is
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.